North America Breast Lesion Localization Methods Market

Market Overview

The North America breast lesion localization methods market size has witnessed significant growth in the past and is expected to grow at a CAGR of 13.5% during the forecast period (2022–2031).

Several breast lesion localization methods are available, including MRI, ultrasound, and mammography. However, its acceptance varies depending on the system’s healthcare infrastructure.

North America boasts a robust healthcare infrastructure, focusing on the breast lesion localization methods market. Among the countries in the region, the United States holds the largest market share, benefiting from its well-established pharmaceutical and healthcare provider presence. The U.S. government allocates significant funds annually for the development of healthcare infrastructure. Additionally, efforts are made to enhance the accessibility and affordability of healthcare, including reimbursement and incentives for certain treatments, particularly for cancer patients.

Market Dynamics

North America Breast Lesion Localization Methods Market Drivers

Increasing Prevalence of Breast Cancer

The shifting market dynamics and increased presence of IT companies have decreased people's focus on their physical well-being. A sedentary lifestyle reinforces this. As more women have joined the workforce, they spend less time cooking and opt for high-calorie packaged and fast foods. This change in dietary habits has contributed to the rise of obesity, a significant factor in the increasing incidence of breast cancer. Additionally, the higher consumption of alcohol is further exacerbating the prevalence of breast cancer.

Rapidly Increasing Penetration of Health Insurance

The expensive nature of cancer treatment is a significant barrier to market growth. However, there has been an increase in the number of individuals purchasing healthcare insurance plans. These countries offer some of the most affordable healthcare insurance plans. This has led to greater access to health insurance coverage, relieving concerns about cancer treatment's cost. As a result, more individuals are likely to seek the expertise of oncologists, knowing that the financial burden will be somewhat alleviated.

North America Breast Lesion Localization Methods Market Restraint

Shortage of Skilled Oncologists and Limited Healthcare Infrastructure

Enough oncologists are necessary to effectively diagnose, treat, and care for cancer patients. However, there is a significant shortage of oncologists capable of delivering high-quality care. Furthermore, the availability of advanced localization technology is limited to developed countries due to inadequate healthcare infrastructure in other regions. Additionally, many hospitals with oncology departments lack the necessary equipment and technologies to diagnose and treat breast cancer.

North America Breast Lesion Localization Methods Market Opportunities

Developing Economies to Offer Lucrative Growth Opportunities

The rapid urbanization in these countries has led to increased migration to cities, prompting government and private entities to expand healthcare infrastructure. Our research indicates that government hospitals in these regions lack adequate technology, leading private hospitals to invest heavily in acquiring new equipment to attract more patients and capitalize on the gap in public healthcare. Furthermore, these governments are providing incentives to encourage the establishment of new hospitals, including offering affordable or free land, incentives per patient treatment, subsidies on treatment costs, and easy loan facilities for purchasing necessary machinery. Consequently, many private players construct hospitals and expand their networks to establish their brands and enhance their market presence.

Regional Analysis

The Breast Lesion Localization Methods Market is segmented by country: the U.S., Canada, and Mexico. The U.S. dominated the market with a CAGR of 13.5% during the forecast period.

North America dominates the breast lesion localization methods market, with the United States leading the region. The presence of advanced healthcare infrastructure, extensive research and development activities, and strong investments contribute to the market's growth. Additionally, increased awareness, favorable reimbursement policies, and the rising incidence of breast cancer drive the demand for localization methods in North America.

The U.S.

The United States is North America's leading market for breast lesion localization methods. The country has a well-established healthcare infrastructure and a strong presence of pharmaceutical and healthcare providers. With a focus on innovation and technological advancements, the U.S. market offers various localization methods for breast lesions.

Canada

Canada's breast lesion localization methods market is a significant segment in the region. The country has a well-developed healthcare system and is known for its high-quality medical services. Government initiatives, technological advancements, and increasing awareness contribute to the market's growth, creating opportunities for market players.

Segmental Analysis

The North America Breast Lesion Localization Methods market is segmented into type and usage.

By type, it is further segmented into wire localization, radioisotope localization, magnetic localization, and others.

Wire localization dominated the market and is expected to register a CAGR of 13.9% over the forecast period. Wire localization is used to identify the lesion's exact location, which aids the surgeon in detecting and removing breast lesions without difficulty if the X-ray detects multiple lesions. This method removes lesions or tumors that are difficult to locate and cannot be felt. In addition, it can be used to remove the smallest possible area, which would be difficult for the surgeon to do without causing visible harm to the surrounding tissue. Some women may experience vertigo or pressure during the painless procedure.

It is further segmented based on usage into tumor identification and sentinel lymph node identification.

Tumor identification dominated the market and is expected to register a CAGR of 13.1% over the forecast period. A triple test is administered for tumor identification, including a physical examination, breast imaging, mammography, and a biopsy. The majority of patients are breast cancer patients. Mammography involves using X-rays to image a breast region containing a tumor. Other imaging technologies, such as MRI and ultrasound, are also employed. Ultrasound is predominantly recommended for women under 30 years old.

Recent Developments

• January 2021: Hologic, Inc., an innovative medical technology company focused on improving women’s health, announced and completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately USD 64 million. The company was previously owned by E-Med Solutions GmbH, Berlin, a group of investors led by German private equity company Westlake Partners.